Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
Arterial hypertension
Cardiovascular risk factor
Chronic kidney disease
Diabetes mellitus
JAK2
Myeloproliferative neoplasm
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
received:
31
07
2023
accepted:
24
08
2023
medline:
15
4
2024
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
ppublish
Résumé
The exact prognostic role of cardiovascular (CV) risk factors in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms (MPNs) remains unknown as it is often masked by other MPN-related features that bear strong prognostic impact on thrombotic risk. Therefore, current MPN treatment is not primarily guided by presence of CV risk factors. Treatment of CV risk factors in MPN patients usually mirrors that from the general population, despite the fact that CV risk factors in MPNs have their own specificities. Moreover, the optimal target levels for different metabolic deflections in MPNs (i.e., low-density lipoprotein, serum uric acid, or glycated hemoglobin levels) have not been defined. In the current review, we separately discuss the most important aspects of every individual CV risk factor (arterial hypertension, hyperlipidemia, chronic kidney disease, smoking, diabetes mellitus, hyperuricemia, and obesity and cachexia) in MPNs, summarize recent advances in the field, and propose future directions and research areas which may be needed to appropriately manage CV risk factors in MPNs.
Identifiants
pubmed: 37665349
doi: 10.1007/s00277-023-05426-9
pii: 10.1007/s00277-023-05426-9
doi:
Substances chimiques
Uric Acid
268B43MJ25
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1513-1523Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Krecak I, Lucijanic M, Verstovsek S (2022) Advances in risk stratification and treatment of polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep 17(5):155–169. https://doi.org/10.1007/s11899-022-00670-8
doi: 10.1007/s11899-022-00670-8
pubmed: 35932395
Hasselbalch HC, Bjørn ME (2015) MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm 2015:102476. https://doi.org/10.1155/2015/102476
doi: 10.1155/2015/102476
pubmed: 26604428
pmcid: 4641200
Holik H, Krečak I, Lucijanić M, Samardžić I, Pilipac D, Vučinić Ljubičić I, Coha B, Kitter Pipić A, Miškić B, Zupančić-Šalek S (2023) Hip and knee osteoarthritis in patients with chronic myeloproliferative neoplasms: a cross-sectional study. Life (Basel) 13(6). https://doi.org/10.3390/life13061388
Lucijanic M, Livun A, Tupek KM, Stoos-Veic T, Aralica G, Gecek I, Pejsa V, Kusec R (2017) Heat shock protein 27 (HSP27/HSPB1) expression is increased in patients with primary and secondary myelofibrosis and may be affecting their survival. Leuk Lymphoma 58(10):2497–2500. https://doi.org/10.1080/10428194.2017.1296146
doi: 10.1080/10428194.2017.1296146
pubmed: 28278711
Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 168(5):317–325. https://doi.org/10.7326/m17-0028
doi: 10.7326/m17-0028
pubmed: 29335713
pmcid: 7533681
Tefferi A, Barbui T (2023) Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. https://doi.org/10.1002/ajh.27002
Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5(11):e369. https://doi.org/10.1038/bcj.2015.94
doi: 10.1038/bcj.2015.94
pubmed: 26617062
pmcid: 4670947
Krecak I, Skelin M, Verstovsek S (2023) Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera. Expert Rev Hematol 16(5):305–316. https://doi.org/10.1080/17474086.2023.2199151
doi: 10.1080/17474086.2023.2199151
pubmed: 37002907
Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128–5133. https://doi.org/10.1182/blood-2012-07-444067
doi: 10.1182/blood-2012-07-444067
pubmed: 23033268
Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T (2020) Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer J 10(2):21. https://doi.org/10.1038/s41408-020-0289-2
doi: 10.1038/s41408-020-0289-2
pubmed: 32098944
pmcid: 7042364
Krečak I, Morić Perić M, Zekanović I, Holik H, Coha B, Gverić-Krečak V, Lucijanić M (2021) No impact of the increased number of cardiovascular risk factors on thrombosis and survival in polycythemia vera. Oncol Res Treat 44(4):201–203. https://doi.org/10.1159/000514347
doi: 10.1159/000514347
pubmed: 33503631
Mancuso S, Santoro M, Accurso V, Agliastro G, Raso S, Di Piazza F, Perez A, Bono M, Russo A, Siragusa S (2020) Cardiovascular risk in polycythemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? Oncol Res Treat 43(10):526–530. https://doi.org/10.1159/000509376
doi: 10.1159/000509376
pubmed: 32772025
Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A (2017) Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J 7(12):662. https://doi.org/10.1038/s41408-017-0035-6
doi: 10.1038/s41408-017-0035-6
pubmed: 29282357
pmcid: 5802551
Sørensen AL, Knudsen TA, Skov V, Kjaer L, Holm N, Ellervik C, Hasselbalch HC (2021) Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: a retrospective cohort study. Br J Haematol 193(1):83–92. https://doi.org/10.1111/bjh.17130
doi: 10.1111/bjh.17130
pubmed: 33169852
Krečak I, Holik H, Coha B, Perić MM, Zekanović I, Krečak MV, Gverić-Krečak V, Lucijanić M (2021) Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera. Ann Hematol 100(5):1335–1336. https://doi.org/10.1007/s00277-021-04431-0
doi: 10.1007/s00277-021-04431-0
pubmed: 33474630
Lekovic D, Gotic M, Sefer D, Mitrovic-Ajtic O, Cokic V, Milic N (2015) Predictors of survival and cause of death in patients with essential thrombocythemia. Eur J Haematol 95(5):461–466. https://doi.org/10.1111/ejh.12517
doi: 10.1111/ejh.12517
pubmed: 25645731
Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N (2023) Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. J Thromb Thrombolysis 55(2):263–272. https://doi.org/10.1007/s11239-022-02751-0
doi: 10.1007/s11239-022-02751-0
pubmed: 36484956
Lekovic D, Gotic M, Milic N, Miljic P, Mitrovic M, Cokic V, Elezovic I (2014) The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia. Med Oncol 31(10):231. https://doi.org/10.1007/s12032-014-0231-1
doi: 10.1007/s12032-014-0231-1
pubmed: 25223529
Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, Radman I, Sertic D, Vodanovic M, Pulanic D, Basic-Kinda S, Durakovic N, Zupancic-Salek S, Vrhovac R, Aurer I, Nemet D, Labar B (2019) Influence of blood count, cardiovascular risks, inherited thrombophilia, and JAK2 V617F burden allele on type of thrombosis in patients with Philadelphia chromosome negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 19(1):53–63. https://doi.org/10.1016/j.clml.2018.08.020
doi: 10.1016/j.clml.2018.08.020
pubmed: 30301673
Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124(19):3021–3023. https://doi.org/10.1182/blood-2014-07-591610
doi: 10.1182/blood-2014-07-591610
pubmed: 25377561
Buxhofer-Ausch V, Olcaydu D, Gisslinger B, Schalling M, Frantal S, Thiele J, Müllauer L, Kvasnicka HM, Watzke H, Kralovics R, Gisslinger H (2014) Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. Eur J Haematol 93(2):103–111. https://doi.org/10.1111/ejh.12307
doi: 10.1111/ejh.12307
pubmed: 24617727
Rusak T, Misztal T, Piszcz J, Tomasiak M (2014) Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients. Free Radic Res 48(2):230–238. https://doi.org/10.3109/10715762.2013.860225
doi: 10.3109/10715762.2013.860225
pubmed: 24180690
Zidek W, Tenschert W, Karoff C, Vetter H (1985) Treatment of resistant hypertension by phlebotomy. Klin Wochenschr 63(16):762–764. https://doi.org/10.1007/bf01733828
doi: 10.1007/bf01733828
pubmed: 4046500
Xiong XJ, Wang PQ, Li SJ (2019) Blood-letting therapy for hypertension: a systematic review and meta-analysis of randomized controlled trials. Chin J Integr Med 25(2):139–146. https://doi.org/10.1007/s11655-018-3009-2
doi: 10.1007/s11655-018-3009-2
pubmed: 29959751
Satou R, Penrose H, Navar LG (2018) Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep 20(12):100. https://doi.org/10.1007/s11906-018-0900-0
doi: 10.1007/s11906-018-0900-0
pubmed: 30291560
pmcid: 6203444
Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, Borghi C, Piani F, Cara-Fuentes G, Bjornstad P, Lanaspa MA, Johnson RJ (2020) Uric acid and hypertension: an update with recommendations. Am J Hypertens 33(7):583–594. https://doi.org/10.1093/ajh/hpaa044
doi: 10.1093/ajh/hpaa044
pubmed: 32179896
pmcid: 7368167
Vlahakos DV, Kosmas EN, Dimopoulou I, Ikonomou E, Jullien G, Vassilakos P, Marathias KP (1999) Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 106(2):158–164. https://doi.org/10.1016/s0002-9343(98)00390-8
doi: 10.1016/s0002-9343(98)00390-8
pubmed: 10230744
Vrsalovic MM, Pejsa V, Veic TS, Kolonic SO, Ajdukovic R, Haris V, Jaksic O, Kusec R (2007) Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status. Cancer Biol Ther 6(9):1434–1436. https://doi.org/10.4161/cbt.6.9.4568
doi: 10.4161/cbt.6.9.4568
pubmed: 17873518
Barbui T, Masciulli A, Ghirardi A, Carobbio A (2017) ACE inhibitors and cytoreductive therapy in polycythemia vera. Blood 129(9):1226–1227. https://doi.org/10.1182/blood-2016-11-752600
doi: 10.1182/blood-2016-11-752600
pubmed: 28028024
Krečak I, Morić Perić M, Zekanović I, Holik H, Coha B, Gverić-Krečak V, Lucijanić M (2021) Beneficial effect of ACE inhibitors on kidney function in polycythemia vera. Wien Klin Wochenschr 133(15-16):808–815. https://doi.org/10.1007/s00508-021-01812-3
doi: 10.1007/s00508-021-01812-3
pubmed: 33555393
Lucijanic M, Veic P, Aric I, Tupek KM, Soric E, Sabljic A, Vlasac Glasnovic J, Stoos-Veic T, Krecak I, Kusec R (2023) Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time. Ann Hematol 102(7):1955–1956. https://doi.org/10.1007/s00277-023-05305-3
doi: 10.1007/s00277-023-05305-3
pubmed: 37269389
Mulas O, Mola B, Costa A, Pittau F, Mantovani D, Dessì S, Fronteddu A, La Nasa G, Caocci G (2023) Renin-angiotensin inhibitors reduce thrombotic complications in essential thrombocythemia and polycythemia vera patients with arterial hypertension. Ann Hematol. https://doi.org/10.1007/s00277-023-05417-w
Akdi A, Özeke Ö, Karanfil M, Ertem AG, Yayla Ç, Demirtaş K, Güney T, Ünal S, Selçuk MT (2020) Diurnal rhythm of blood pressure in patients with polycythemia vera. Blood Press Monit 25(2):69–74. https://doi.org/10.1097/mbp.0000000000000427
doi: 10.1097/mbp.0000000000000427
pubmed: 31913148
Jóźwik-Plebanek K, Dobrowolski P, Lewandowski J, Narkiewicz K, Sikorska A, Siński M, Eisenhofer G, Schmieder RE, Januszewicz M, Windyga J, Prejbisz A, Januszewicz A (2020) Blood pressure profile, sympathetic nervous system activity, and subclinical target organ damage in patients with polycythemia vera. Pol Arch Intern Med 130(7-8):607–614. https://doi.org/10.20452/pamw.15473
doi: 10.20452/pamw.15473
pubmed: 32621668
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455
doi: 10.1093/eurheartj/ehz455
pubmed: 31504418
Fujita H, Hamaki T, Handa N, Ohwada A, Tomiyama J, Nishimura S (2012) Hypocholesterolemia in patients with polycythemia vera. J Clin Exp Hematop 52(2):85–89. https://doi.org/10.3960/jslrt.52.85
doi: 10.3960/jslrt.52.85
pubmed: 23037623
Krečak I, Holik H, Morić-Perić M, Zekanović I, Coha B, Gverić-Krečak V (2020) The impact of statins on the intensity of phlebotomies in polycythemia vera. Ann Hematol 99(4):911–912. https://doi.org/10.1007/s00277-020-03950-6
doi: 10.1007/s00277-020-03950-6
pubmed: 32025841
Podoltsev N, Zhu M, Wang R, Zeidan AM, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X (2018) Use of statins, survival and incidence of thrombosis among older adults with polycythemia vera: a population-based study. Blood 132(Supplement 1):3580–3580. https://doi.org/10.1182/blood-2018-99-119272
doi: 10.1182/blood-2018-99-119272
Kristensen DT, Øvlisen AK, Jakobsen LH, Severinsen MT, Hannig LH, Starklint J, Hilsøe MH, Vallentin AP, Brabrand M, Hasselbalch HC, El-Galaly TC, Roug AS (2023) Use of statins and risk of myeloproliferative neoplasms — a Danish nationwide case-control study. Blood Adv. https://doi.org/10.1182/bloodadvances.2023009784
Lucijanic M, Galusic D, Krecak I, Sedinic M, Holik H, Perisa V, Moric Peric M, Zekanovic I, Stoos-Veic T, Kusec R (2020) Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis. Ann Hematol 99(12):2779–2785. https://doi.org/10.1007/s00277-020-04239-4
doi: 10.1007/s00277-020-04239-4
pubmed: 32862283
Krečak I, Holik H, Martina MP, Zekanović I, Coha B, Gverić-Krečak V (2020) Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera. Int J Hematol 112(3):377–384. https://doi.org/10.1007/s12185-020-02898-7
doi: 10.1007/s12185-020-02898-7
pubmed: 32514928
Christensen AS, Møller JB, Hasselbalch HC (2014) Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res 38(4):490–495. https://doi.org/10.1016/j.leukres.2014.01.014
doi: 10.1016/j.leukres.2014.01.014
pubmed: 24630365
Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, Komatsu N (2019) Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica 104(11):e506–e509. https://doi.org/10.3324/haematol.2018.208876
doi: 10.3324/haematol.2018.208876
pubmed: 30948490
pmcid: 6821608
Gecht J, Tsoukakis I, Kricheldorf K, Stegelmann F, Klausmann M, Griesshammer M, Schulz H, Hollburg W, Göthert JR, Sockel K, Heidel FH, Gattermann N, Maintz C, Al-Ali HK, Platzbecker U, Hansen R, Hänel M, Parmentier S, Bommer M et al (2021) Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German Study Group for MPN Bioregistry. Cancers (Basel) 13(16). https://doi.org/10.3390/cancers13164086
Krečak I, Holik H, Morić Perić M, Zekanović I, Coha B, Lucijanić M (2022) Chronic kidney disease has a higher prevalence in polycythemia vera than in secondary polycythemia, a matched case–control analysis. Indian J Hematol Blood Transfus. https://doi.org/10.1007/s12288-022-01624-z
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD (2016) Global prevalence of chronic kidney disease — a systematic review and meta-analysis. PloS One 11(7):e0158765. https://doi.org/10.1371/journal.pone.0158765
doi: 10.1371/journal.pone.0158765
pubmed: 27383068
pmcid: 4934905
Krečak I, Holik H, Lucijanić M (2022) The prevalence of simple kidney cysts in polycythemia vera and its clinical associations. Indian J Hematol Blood Transfus 38(2):429–431. https://doi.org/10.1007/s12288-021-01515-9
doi: 10.1007/s12288-021-01515-9
pubmed: 35496964
pmcid: 9001796
Lucijanic M, Krecak I, Kusec R (2022) Renal disease associated with chronic myeloproliferative neoplasms. Expert Rev Hematol 15(2):93–96. https://doi.org/10.1080/17474086.2022.2039117
doi: 10.1080/17474086.2022.2039117
pubmed: 35125041
Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, Herrmann S, Tefferi A, D’Agati VD, Nasr SH (2011) Myeloproliferative neoplasms cause glomerulopathy. Kidney Int 80(7):753–759. https://doi.org/10.1038/ki.2011.147
doi: 10.1038/ki.2011.147
pubmed: 21654720
Alexander MP, Nasr SH, Kurtin PJ, Casey ET, Hernandez LP, Fidler ME, Sethi S, Cornell LD (2015) Renal extramedullary hematopoiesis: interstitial and glomerular pathology. Mod Pathol 28(12):1574–1583. https://doi.org/10.1038/modpathol.2015.117
doi: 10.1038/modpathol.2015.117
pubmed: 26449764
Büttner-Herold M, Sticht C, Wiech T, Porubsky S (2021) Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms. Histopathology 78(5):738–748. https://doi.org/10.1111/his.14282
doi: 10.1111/his.14282
pubmed: 33078472
Person F, Meyer SC, Hopfer H, Menter T (2021) Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Virchows Arch 479(5):1013–1020. https://doi.org/10.1007/s00428-021-03129-y
doi: 10.1007/s00428-021-03129-y
pubmed: 34164707
pmcid: 8572822
Holik H, Lucijanic M, Krecak I (2023) Specific symptom burden in patients with chronic myeloproliferative neoplasms and chronic kidney disease. Ann Hematol 102(7):1963–1965. https://doi.org/10.1007/s00277-023-05296-1
doi: 10.1007/s00277-023-05296-1
pubmed: 37256304
Larsen MK, Skov V, Kjaer L, Møller-Palacino NA, Pedersen RK, Andersen M, Ottesen JT, Cordua S, Poulsen HE, Dahl M, Knudsen TA, Eickhardt-Dalbøge CS, Koschmieder S, Pedersen KM, Çolak Y, Bojesen SE, Nordestgaard BG, Stiehl T, Hasselbalch HC, Ellervik C (2022) Clonal haematopoiesis of indeterminate potential and impaired kidney function—a Danish general population study with 11 years follow-up. Eur J Haematol 109(5):576–585. https://doi.org/10.1111/ejh.13845
doi: 10.1111/ejh.13845
pubmed: 36054308
pmcid: 9804367
Vlasschaert C, McNaughton AJM, Chong M, Cook EK, Hopman W, Kestenbaum B, Robinson-Cohen C, Garland J, Moran SM, Paré G, Clase CM, Tang M, Levin A, Holden R, Rauh MJ, Lanktree MB (2022) Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J Am Soc Nephrol 33(5):985–995. https://doi.org/10.1681/asn.2021060774
doi: 10.1681/asn.2021060774
pubmed: 35197325
pmcid: 9063886
Dawoud AAZ, Gilbert RD, Tapper WJ, Cross NCP (2022) Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia 36(2):507–515. https://doi.org/10.1038/s41375-021-01382-3
doi: 10.1038/s41375-021-01382-3
pubmed: 34413458
Barbui T, Carobbio A, De Stefano V (2022) Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost 6(1):e12657. https://doi.org/10.1002/rth2.12657
doi: 10.1002/rth2.12657
pubmed: 35155976
pmcid: 8822262
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–33. https://doi.org/10.1056/NEJMoa1208500
doi: 10.1056/NEJMoa1208500
pubmed: 23216616
Trivedi PM, Graham KL, Scott NA, Jenkins MR, Majaw S, Sutherland RM, Fynch S, Lew AM, Burns CJ, Krishnamurthy B, Brodnicki TC, Mannering SI, Kay TW, Thomas HE (2017) Repurposed JAK1/JAK2 inhibitor reverses established autoimmune insulitis in NOD mice. Diabetes 66(6):1650–1660. https://doi.org/10.2337/db16-1250
doi: 10.2337/db16-1250
pubmed: 28292965
Botana M, Escalada J, Merchante Á, Reyes R, Rozas P (2022) Prevention of cardiorenal complications with sodium-glucose cotransporter type 2 inhibitors: a narrative review. Diabetes Ther 13(Suppl 1):5–17. https://doi.org/10.1007/s13300-022-01277-1
doi: 10.1007/s13300-022-01277-1
pubmed: 35704166
pmcid: 9240141
Gangat N, Reichard K, Tefferi A (2023) Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: impact on hemoglobin/hematocrit levels and outcomes among 11 consecutive patients. Am J Hematol. https://doi.org/10.1002/ajh.27048
Gangat N, Alkhateeb H, Reichard K, Tefferi A (2023) Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: a Mayo Clinic series of nine consecutive cases. Am J Hematol. https://doi.org/10.1002/ajh.27034
Gangat N, Abdallah M, Szuber N, Saliba A, Alkhateeb H, Al-Kali A, Begna KH, Pardanani A, Tefferi A (2023) Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. Am J Hematol 98(7):E165–e167. https://doi.org/10.1002/ajh.26933
doi: 10.1002/ajh.26933
pubmed: 37073574
Krečak I, Zekanović I, Holik H, Morić Perić M, Coha B, Gverić-Krečak V (2022) Estimating plasma volume using the Strauss-derived formula may improve prognostication in polycythemia vera. Int J Lab Hematol 44(2):e69–e71. https://doi.org/10.1111/ijlh.13716
doi: 10.1111/ijlh.13716
pubmed: 34581007
Lucijanic M, Krecak I, Soric E, Sabljic A, Galusic D, Holik H, Perisa V, Peric MM, Zekanovic I, Kusec R (2023) Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis. Biochem Med (Zagreb) 33(2):020901. https://doi.org/10.11613/bm.2023.020901
doi: 10.11613/bm.2023.020901
pubmed: 37143717
Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154(8):554–559. https://doi.org/10.7326/0003-4819-154-8-201104190-00007
doi: 10.7326/0003-4819-154-8-201104190-00007
pubmed: 21502652
Ren Q, Lv X, Yang L, Yue J, Luo Y, Zhou L, Meng S, Yang S, Puchi B, Zhou X, Ji L (2020) Erythrocytosis and performance of HbA1c in detecting diabetes on an oxygen-deficient plateau: a population-based study. J Clin Endocrinol Metab 105(4). https://doi.org/10.1210/clinem/dgaa001
Karsegard J, Wicky J, Mensi N, Caulfield A, Philippe J (1997) Spurious glycohemoglobin values associated with hydroxyurea treatment. Diabetes Care 20(7):1211–1212. https://doi.org/10.2337/diacare.20.7.1211
doi: 10.2337/diacare.20.7.1211
pubmed: 9203471
Christensen SF, Scherber RM, Mazza GL, Dueck AC, Brochmann N, Andersen CL, Hasselbalch HC, Mesa RA, Geyer HL (2021) Tobacco use in the myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer 21(1):691. https://doi.org/10.1186/s12885-021-08439-7
doi: 10.1186/s12885-021-08439-7
pubmed: 34112113
pmcid: 8194237
Lindholm Sørensen A, Hasselbalch HC (2016) Smoking and philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol 97(1):63–69. https://doi.org/10.1111/ejh.12684
doi: 10.1111/ejh.12684
pubmed: 26384085
Duncombe AS, Anderson LA, James G, de Vocht F, Fritschi L, Mesa R, Clarke M, McMullin MF (2020) Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. Hemasphere 4(1):e327. https://doi.org/10.1097/hs9.0000000000000327
doi: 10.1097/hs9.0000000000000327
pubmed: 32072143
pmcid: 7000482
Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, Redon J, Stack AG, Tsioufis KP (2020) Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med 80:1–11. https://doi.org/10.1016/j.ejim.2020.07.006
doi: 10.1016/j.ejim.2020.07.006
pubmed: 32739239
Gonzalez-Martin G, Cano J, Carriazo S, Kanbay M, Perez-Gomez MV, Fernandez-Prado R, Ortiz A (2020) The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality. Clin Kidney J 13(6):936–947. https://doi.org/10.1093/ckj/sfaa236
doi: 10.1093/ckj/sfaa236
pubmed: 33391737
pmcid: 7769546
Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, Struthers AD, Begg AG, Wei L, Avery AJ, Taggar JS, Walker A, Duce SL, Barr RJ, Dumbleton JS, Rooke ED, Townend JN, Ritchie LD, MacDonald TM (2022) Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400(10359):1195–1205. https://doi.org/10.1016/s0140-6736(22)01657-9
doi: 10.1016/s0140-6736(22)01657-9
pubmed: 36216006
Yu T, Weinreb N, Wittman R, Wasserman LR (1976) Secondary gout associated with chronic myeloproliferative disorders. Semin Arthritis Rheum 5(3):247–256. https://doi.org/10.1016/0049-0172(76)90026-3
doi: 10.1016/0049-0172(76)90026-3
pubmed: 1062009
Krecak I, Lucijanic M, Gveric-Krecak V, Durakovic N (2020) Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera. Leuk Lymphoma. https://doi.org/10.1080/10428194.2020.1731503
Lucijanic M, Krecak I, Galusic D, Sedinic M, Holik H, Perisa V, Moric Peric M, Zekanovic I, Stoos-Veic T, Pejsa V, Kusec R (2022) Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis. Wien Klin Wochenschr 134(3-4):97–103. https://doi.org/10.1007/s00508-020-01802-x
doi: 10.1007/s00508-020-01802-x
pubmed: 33464403
Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ (2019) Obesity paradox in cardiovascular disease: where do we stand? Vasc Health Risk Manag 15:89–100. https://doi.org/10.2147/vhrm.S168946
doi: 10.2147/vhrm.S168946
pubmed: 31118651
pmcid: 6503652
Christensen SF, Scherber RM, Brochmann N, Goros M, Gelfond J, Andersen CL, Flachs EM, Mesa R (2020) Body mass index and total symptom burden in myeloproliferative neoplasms discovery of a U-shaped association. Cancers (Basel) 12(8). https://doi.org/10.3390/cancers12082202
Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D’Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L et al (2021) Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematol Oncol 39(3):409–418. https://doi.org/10.1002/hon.2843
doi: 10.1002/hon.2843
pubmed: 33590502
Leiba A, Duek A, Afek A, Derazne E, Leiba M (2017) Obesity and related risk of myeloproliferative neoplasms among israeli adolescents. Obesity (Silver Spring) 25(7):1187–1190. https://doi.org/10.1002/oby.21863
doi: 10.1002/oby.21863
pubmed: 28500663
Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK (2023) Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel) 15(2). https://doi.org/10.3390/cancers15020485
BHL H, Macaulay VM, Harris DA, Klenerman P, Karpe F, Lord SR, Harris AL, Buffa FM (2022) Obesity: a perfect storm for carcinogenesis. Cancer Metastasis Rev 41(3):491–515. https://doi.org/10.1007/s10555-022-10046-2
doi: 10.1007/s10555-022-10046-2
Liu XZ, Pedersen L, Halberg N (2021) Cellular mechanisms linking cancers to obesity. Cell Stress 5(5):55–72. https://doi.org/10.15698/cst2021.05.248
doi: 10.15698/cst2021.05.248
pubmed: 33987528
pmcid: 8090860
Lucijanic M, Veletic I, Rahelic D, Pejsa V, Cicic D, Skelin M, Livun A, Tupek KM, Stoos-Veic T, Lucijanic T, Maglicic A, Kusec R (2018) Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wien Klin Wochenschr 130(3-4):126–133. https://doi.org/10.1007/s00508-018-1318-z
doi: 10.1007/s00508-018-1318-z
pubmed: 29372410
Tefferi A, Nicolosi M, Penna D, Mudireddy M, Szuber N, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani AD (2018) Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. Blood Adv 2(15):1980–1984. https://doi.org/10.1182/bloodadvances.2018018051
doi: 10.1182/bloodadvances.2018018051
pubmed: 30097464
pmcid: 6093731
Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D’Adda M, Crugnola M, Bosi C, Heidel F, Molica M et al (2019) Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Ann Hematol 98(4):889–896. https://doi.org/10.1007/s00277-018-3569-1
doi: 10.1007/s00277-018-3569-1
pubmed: 30515542
Lucijanic M, Galusic D, Soric E, Sedinic M, Cubela M, Huzjan Korunic R, Pejsa V, Kusec R (2021) Ruxolitinib treatment improves muscle mass in patients with myelofibrosis. Ann Hematol 100(4):1105–1106. https://doi.org/10.1007/s00277-020-04243-8
doi: 10.1007/s00277-020-04243-8
pubmed: 32870367
Mollé N, Krichevsky S, Kermani P, Silver RT, Ritchie E, Scandura JM (2020) Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood 135(13):1062–1066. https://doi.org/10.1182/blood.2019003050
doi: 10.1182/blood.2019003050
pubmed: 32047890
Leiva O, Jenkins A, Rosovsky RP, Leaf RK, Goodarzi K, Hobbs G (2023) Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation. J Cardiol 81(3):260–267. https://doi.org/10.1016/j.jjcc.2022.10.007
doi: 10.1016/j.jjcc.2022.10.007
pubmed: 36384716
Krečak I, Pivac L, Lucijanić M, Skelin M (2023) Polypharmacy, potentially inappropriate medications, and drug-to-drug interactions in patients with chronic myeloproliferative neoplasms. Biomedicines 11(5). https://doi.org/10.3390/biomedicines11051301
Verstovsek S, Krečak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, Zaiac M, Morelli M, Smyth A, Redondo S, Bigan E, Ruhl M, Meier C, Beffy M (1925) Kiladjian J-J (2023) Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: the Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project. Biomedicines 11(7)